Device Or Drug? Canada Updates Classification Guidance For Difficult To Distinguish Products
Health Canada’s revised guidance on classifying products at the device-drug interface reflects legislative changes the government has made. The agency also says that previous classification decisions may need to be reviewed in the light of new scientific and other evidence.
You may also be interested in...
Health technology assessment body NICE wants Kite to collect more evidence to prove that Tecartus can cure relapsed or refractory mantle cell lymphoma. But in the meantime, it says the CAR-T therapy should be made available on the National Health Service, making UK patients among the first in the world to be offered access to the treatment.
New medicines under evaluation at the European Medicines Agency.
The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.